Hydrokortisonihoito elinluovutuspotilailla (HYDRO) - HYDRO

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-001909-41-FI

Enrollment

Registered

2008-04-01

Start date

2008-04-11

Completion date

Unknown

Last updated

2020-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tutkittavilla on vakava aivovamma ja/tai lukinkalvonalainen verenvuoto, eikä heitä voida parantaa sairaudestaan. Heitä hoidetaan teho-osastolla mahdollisina elintenluovutuspotilaina. MedDRA version: 9.1 Level: LLT Classification code 10019587 Term: Hemorrhage subarachnoid MedDRA version: 9.1 Level: LLT Classification code 10049054 Term: Brain death MedDRA version: 9.1 Level: LLT Classification code 10052346 Term: Brain contusion MedDRA version: 9.1 Level: LLT Classification code 10006117 Ter

Interventions

Trade Name: Solu-Cortef Pharmaceutical Form: INN or Proposed INN: HYDROCORTISONE SODIUM SUCCINATE CAS Number: 125042 Pharmaceutical form of the placebo: Injection* Route of administration of the plac

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026